Columnist Sam Kirton encourages the IPF community to get a jump on legislative advocacy before the new congressional term begins.

CAL101, an investigational therapy with the potential to treat pulmonary fibrosis, showed a favorable safety and pharmacological profile in a Phase 1 clinical trial, according to results announced by ...

How is it already November? Here in the U.S., today is Election Day, so get out and vote if you haven’t already done so. I wanted to take the opportunity this week to update you on topics I’ve ...